InMed Pharmaceuticals Inc. (NASDAQ: INM) Announce Publication Of Study Assessing CBN In Glaucoma Treatment

InMed Pharmaceuticals Inc. (NASDAQ: INM) has announced the publication of an article in a peer-reviewed journal Biochimica et Biophysical Acta (BBA – Molecular Basis of Disease), entitled “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma.”

The Biochimica et Biophysical Acta journal focuses on molecular genetics and biochemistry of disease processes and human disease models ranging from cancer, aging, immunological, neurological, and metabolic diseases.

In vivo and in vitro studies to assess CBN

The peer-reviewed article focuses on studies on the use of cannabinol, or CBN, as a viable glaucoma treatment. Several trials using in vitro and in vivo glaucoma models were undertaken to assess the survival of retinal ganglion cells, intraocular pressure regulation, and its impact on extracellular matrix proteins.

Two significant findings emerged from these studies: first, CBN may increase neuroprotection of vision-producing cells in the retina, and second, CBN may restore intraocular pressure by reducing alterations in extracellular matrix proteins. Also, the article compares CBN to other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD), finding that CBN had a stronger effect and a larger neuroprotective therapeutic range.

InMed Scientific Advisor Mauro Maccarrone “Having this research peer-reviewed and published in such a reputable journal is a significant milestone for InMed’s glaucoma development program. This provides important external validation for the scientific community as the program advances towards human studies. We believe InMed’s INM-088 program has significant implications for neuroprotection within the glaucoma space and may lead to a potential new treatment for millions of people suffering from this condition worldwide.”

Findings indicate the therapeutic potential of CBN

Professor Ujendra Kumar, corresponding author, Faculty of Pharmaceuticals, The University of British Columbia, commented, “The observations in this study indicate the therapeutic potential for the use of CBN in the treatment of glaucoma. Not only does the data suggest a reduction in ocular pressure but also proactive neuroprotection in the retina, both of which are integral to the treatment of glaucoma. This publication is further evidence to suggest rare cannabinoids have therapeutic potential to treat various diseases.”